Eli Lilly & Co: The Story Behind The Increasing Demand vs. Production of Orforglipron & Progress of Other Drugs!

In Q1 2024, Eli Lilly and Company achieved strong growth and strategic milestones, with revenue growing by 26% and new products increasing by nearly $1.8 billion in comparison to the same period last year. The company’s new products, primarily Mounjaro and Zepbound, primarily drove the growth. Eli Lilly also accomplished various pipeline milestones during this period. The outlook remains positive with the company set to achieve accelerated growth throughout the year due to continuous business momentum. The company plans to invest heavily in people, product launches, pipeline development, and manufacturing capacity.